within Pharmacolibrary.Drugs.ATC.D;

model D11AH04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 0.007916666666666666,
    adminDuration  = 600,
    adminMass      = 0.03,
    adminCount     = 1,
    Vd             = 0.0116,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.004666666666666667,
    Tlag           = 10.200000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Alitretinoin (9-cis-retinoic acid) is an endogenous retinoid, a derivative of vitamin A, used as an oral medication primarily for the treatment of severe chronic hand eczema unresponsive to topical corticosteroids. It is also investigated for use in certain cancers and cutaneous lesions associated with Kaposi's sarcoma. Alitretinoin is approved for use in several countries for dermatologic indications.</p><h4>Pharmacokinetics</h4><p>Typical pharmacokinetics in healthy adult volunteers following oral administration.</p><h4>References</h4><ol><li><p>Schmitt-Hoffmann, AH, et al., &amp; Kovacs, P (2012). Oral alitretinoin: a review of the clinical pharmacokinetics and pharmacodynamics. <i>Expert review of clinical pharmacology</i> 5(4) 373–388. DOI:<a href=&quot;https://doi.org/10.1586/ecp.12.26&quot;>10.1586/ecp.12.26</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/22943117/&quot;>https://pubmed.ncbi.nlm.nih.gov/22943117</a></p></li><li><p>Schmitt-Hoffmann, AH, et al., &amp; Maares, J (2011). Influence of alitretinoin on the pharmacokinetics of the oral contraceptive ethinyl estradiol/norgestimate. <i>Clinical and experimental dermatology</i> 36 Suppl 2 4–11. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2230.2011.04031.x&quot;>10.1111/j.1365-2230.2011.04031.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21443598/&quot;>https://pubmed.ncbi.nlm.nih.gov/21443598</a></p></li><li><p>Schmitt-Hoffmann, AH, et al., &amp; Maares, J (2011). Influence of food on the pharmacokinetics of oral alitretinoin (9-cis retinoic acid). <i>Clinical and experimental dermatology</i> 36 Suppl 2 18–23. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2230.2011.04033.x&quot;>10.1111/j.1365-2230.2011.04033.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21443600/&quot;>https://pubmed.ncbi.nlm.nih.gov/21443600</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end D11AH04;
